Seyirt, SedaTezel, Basar UymazSanlibaba, Pinar2025-01-272025-01-2720240145-88921745-4549https://doi.org/10.1155/2024/1619353https://hdl.handle.net/20.500.12428/24097The objective of this study was to enumerate and identify Lactobacillus spp. and Bifidobacterium spp. from 70 samples of commercial dairy probiotic products and assess the antibiotic resistance profile of these probiotic cultures. Viable Lactobacillus spp. and Bifidobacterium spp. were not detected in 13 of 70 probiotic dairy products. Fifty-six products with specific claims of viable bacteria met or exceeded their label claim. Only one of the tested products had a lower number of viable bacteria than stated on the label. Based on the label claims, 11 samples explicitly indicated the presence of monoculture Bifidobacterium spp. strains. Meanwhile, 36 samples were labelled as containing a combination of Lactobacillus spp. and Bifidobacterium spp. species. However, 23 samples did not provide detailed information about the specific probiotic species present. The disc diffusion method was used for determining antibiotic resistance. High levels of resistance to methicillin (100%), vancomycin (95.3%), and cefoxitin (90.7%) were observed in Lactobacillus spp. strains. Bifidobacterium spp. strains were determined to have high frequencies of resistance to cefoxitin (100%), vancomycin (100%), and methicillin (95.6%). Finally, MDR rates were found to be 100% in Bifidobacterium and 95.3% in Lactobacillus species. Antibiotic resistance should be regarded as a significant part of the safety assessment of probiotics. Novel approaches will be essential for addressing MDR bacteria.eninfo:eu-repo/semantics/openAccessantibiotic resistanceBifidobacterium spp.identificationLactobacillus spp.probiotic productsArticle202410.1155/2024/1619353N/AWOS:0013392697000012-s2.0-85207377945Q2